Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPhysiomics Regulatory News (PYC)

Share Price Information for Physiomics (PYC)

Share Price is delayed by 15 minutes
Get Live Data
0.625    -0.025 (-3.85%)
Bid:
0.60
Ask:
0.65
Spread: 0.05 (8.333%)
Market Cap: £2.83m
PYC Live PriceLast checked at - London Stock Exchange

Intraday Physiomics Share Chart

Options Award

23 Dec 2025 07:00

RNS Number : 5646M
Physiomics PLC
23 December 2025
 

23 December 2025

 

Physiomics plc

("Physiomics" or the "Company")

 

Options Award

 

Physiomics plc (AIM: PYC), announces an award of share options (the "Options") over ordinary shares of 0.4 pence each in the capital of the Company ("Ordinary Shares"). The Company considers that it is important to incentivise its key employees to create shareholder value and, as such, today the Board has approved the award of the following options to Mr Jesse Thissen, Head of Biometrics, under the Company's existing share option scheme (the "Scheme"):

1. 1,516,044 Options with an exercise price of 0.41 pence, representing a 41% premium to the closing mid-market price per Ordinary Share on 22 December 2025. All these Options vest on the first anniversary of Mr Thissen's employment, being 1 July 2026.

2. 1,516,044 Options with exercise price of 0.79 pence, representing a 172% premium to the closing mid-market price per Ordinary Share on 22 December 2025. One third of these Options vest on each anniversary of Mr Thissen's employment (33.3% from 1 July 2026, 66.7% from 1 July 2027 and 100% from 1 July 2028)

3. 1,516,044 Options with an exercise price of 1.29 pence, representing a 345% premium to the closing mid-market price per Ordinary Share on 22 December 2025. These Options vest over the same time periods as described under (2) above.

All Options can be exercised within 10 years of the date of grant.

The total number of options issued to date under the Scheme is 4,548,132.

 

Dr Peter Sargent, CEO of Physiomics, commented:

"As the Company pursues growth and a transition to cash generation, the establishment of a scalable second service line represents a significant milestone in this strategy. We are pleased to announce that following Jesse's appointment in July 2025, he has played an integral role in launching our new Biometrics service line. Within the first six months, he has secured and commenced delivery on three contracts supporting new therapies for infectious and immunological diseases. Jesse has demonstrated strong leadership in advancing the Biometrics service line and continues to contribute effectively across the broader organisation."

 

 

 

Enquiries:

 

Physiomics plc

Dr Peter Sargent, CEO

+44 (0)1235 841575

 

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGZMZZZZKGKZZ
Date   Source Headline
28th May 20267:00 amRNS-RHantavirus Translational Modelling Capability
27th May 20267:00 amRNSPhysiomics Awarded Multiple Contract Awards
26th May 20263:48 pmRNSHolding(s) in Company
21st May 20265:21 pmRNSHolding(s) in Company
15th May 20267:00 amRNSUpdate regarding CEO - Peter Sargent
12th May 20267:00 amRNSAppointment of Stewart Williams as Consultant
8th May 20267:00 amRNSStrategy Update
29th Apr 20266:15 pmRNSReplacement Result of Meeting and Board Changes
29th Apr 202611:00 amRNSResults of General Meeting and Board Changes
24th Apr 202610:30 amRNSReminder to Vote Against Resolutions
22nd Apr 20267:00 amRNSLaunch of Website for Requisitioned Meeting
17th Apr 20267:00 amRNSISS Voting Recommendation
14th Apr 20267:00 amRNSPhysiomics Awarded New Contract by Numab
8th Apr 20267:00 amRNSRequestioned GM and Investor Presentation
20th Mar 20269:45 amRNSHolding(s) in Company
20th Mar 20267:00 amRNSCancellation of General Meeting
18th Mar 20262:55 pmRNSResult of WRAP Retail Offer
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:01 amRNSWRAP Retail Offer for up to £110,000.00
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
17th Mar 20267:00 amRNSCompletion of Placing and WRAP Retail Offer Launch
16th Mar 20267:00 amRNSGeneral Meeting Request
16th Mar 20267:00 amRNSGeneral Meeting Request
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
13th Mar 20267:00 amRNSResult of WRAP Retail Offer
11th Mar 20268:00 amRNSHolding(s) in Company
10th Mar 20267:01 amRNSWRAP Retail Offer for up to £49,999.98
16th Feb 20268:37 amRNSInterim Results
13th Feb 20262:23 pmRNSHolding(s) in Company
12th Feb 20267:00 amRNS-RPhysiomics Awarded New Contract
2nd Feb 202611:40 amRNSHolding(s) in Company
28th Jan 20267:00 amRNSPhysiomics Awarded New Contract by Numab
23rd Dec 20257:00 amRNSOptions Award
23rd Dec 20257:00 amRNSOptions Award
15th Dec 20257:00 amRNSPhysiomics Awarded Follow On Contract by UK Client
11th Dec 20257:00 amRNSPhysiomics Awarded New Contract by Numab
10th Dec 20257:00 amRNS-RPhysiomics Awarded New Contract by GARDP
8th Dec 20254:31 pmRNSHolding(s) in Company
4th Dec 20257:00 amRNS-RPhysiomics Awarded Two New Contracts
3rd Dec 20257:00 amRNSBoard Changes
18th Nov 20253:43 pmRNSResult of AGM
17th Oct 20257:00 amRNSNotice of AGM
30th Sep 20257:00 amRNSChange of Registered Office
29th Sep 20257:00 amRNSAnnual Financial Report
22nd Sep 20257:00 amRNSNotice of Results and Investor Presentation
6th Aug 20257:00 amRNSFollow-on Contract with UK Biotech Client
16th Jul 20257:00 amRNSContract Award
14th Jul 20257:00 amRNSTrading Update
10th Jul 20257:00 amRNSPlatform Implementation and Partnership Expansion
1st Jul 20257:00 amRNSContract Award

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.